ATM and nonpapillary renal cell carcinoma: In this study, we conducted detailed analyses of the response of ccRCC cell lines to conventional DNA-damaging chemotherapeutic agents as well as to ATM, ATR, and DNA-PK inhibitors (hereafter termed ATRi, ATMi, and DNA-PKi).